Literature DB >> 27040589

Periocular Reconstruction in Patients with Facial Paralysis.

Shannon S Joseph1, Andrew W Joseph2, Raymond S Douglas1, Guy G Massry3.   

Abstract

Facial paralysis can result in serious ocular consequences. All patients with orbicularis oculi weakness in the setting of facial nerve injury should undergo a thorough ophthalmologic evaluation. The main goal of management in these patients is to protect the ocular surface and preserve visual function. Patients with expected recovery of facial nerve function may only require temporary and conservative measures to protect the ocular surface. Patients with prolonged or unlikely recovery of facial nerve function benefit from surgical rehabilitation of the periorbital complex. Current reconstructive procedures are most commonly intended to improve coverage of the eye but cannot restore blink.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ectropion; Exposure keratopathy; Eyelid retraction; Facial nerve; Facial paralysis; Paralytic lagophthalmos; Synkinesis

Mesh:

Year:  2016        PMID: 27040589     DOI: 10.1016/j.otc.2015.10.011

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  3 in total

1.  Outcome of a graduated minimally invasive facial reanimation in patients with facial paralysis.

Authors:  Laura C Holtmann; Anja Eckstein; Kerstin Stähr; Minzhi Xing; Stephan Lang; Stefan Mattheis
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-04-08       Impact factor: 2.503

2.  Outcomes of lower eyelid retractor recession and lateral horn lysis in lower eyelid elevation for facial nerve palsy.

Authors:  P Tan; J Wong; W F Siah; R Malhotra
Journal:  Eye (Lond)       Date:  2017-09-01       Impact factor: 3.775

3.  Outcomes From Lateral Eyelid Coupling for Facial Paralysis Using the Modified Tarsoconjunctival Flap.

Authors:  Raj Dedhia; Tsung-Yen Hsieh; Oliver Chin; Taha Z Shipchandler; Travis T Tollefson
Journal:  JAMA Facial Plast Surg       Date:  2018-09-01       Impact factor: 4.611

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.